RBC keeps Outperform on ACADIA Pharmaceuticals stock at USD 37

Published on 10/07/2026 at 04:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 307.96 million in the second quarter of 2026, up 14.90 percent. ACADIA Pharmaceuticals stock had EUR 17.49 at the October 5, 2026 prior close.

ACAD, US0042251084, Illustration mit AI erstellt.

ACADIA Pharmaceuticals (ISIN US0042251084) had a prior close of EUR 17.49 at Lang & Schwarz on October 5, 2026. According to Investing.com on October 5, 2026, RBC Capital maintained its Outperform rating and USD 37.00 price target. The rating keeps analyst attention on ACADIA's marketed products and its development pipeline after fresh clinical updates.

RBC keeps its USD 37 target

RBC Capital said ACADIA's base business appears undervalued even before assigning value to pipeline programs or intellectual property linked to Daybue, according to Investing.com on October 5, 2026. The same report said recent patent developments reduce risk around revenue projections for Nuplazid, while the Phase 2 RADIANT program for remlifanserin remains a key clinical test.

The counterweight is trial execution. Investing.com reported that RADIANT narrowly missed its primary endpoint, with H.C. Wainwright lowering its target to USD 33.00 from USD 37.00 and Needham cutting its target to USD 35.00 from USD 40.00 while keeping Buy ratings.

Second-quarter figures beat estimates

ACADIA reported revenue of USD 307.96 million for the second quarter of 2026, versus a USD 295.52 million estimate, while adjusted and GAAP earnings per share were both USD 0.18 against a USD 0.06 estimate, according to Earnings Today. Net income was USD 31.50 million, and revenue was up 14.90 percent from the prior-year quarter.

The results provide a stronger commercial base for the pipeline debate. Cash and cash equivalents stood at USD 384.99 million at June 30, 2026, while operating cash flow reached USD 100.78 million in the second quarter.

Nasdaq range keeps risk visible

ACADIA's market capitalization was USD 3.4 billion as of October 6, 2026. The finance quote showed a Nasdaq 52-week range of USD 19.57 to USD 30.96 on that date, leaving clinical execution and commercial growth as the main variables behind the valuation discussion.

Prior close sets the market reference

ACADIA Pharmaceuticals had a prior close of EUR 17.49 at Lang & Schwarz on October 5, 2026. The reference is separate from the Nasdaq range, which is quoted in USD and dated October 6, 2026. The further course of trading is shown by the continuously updated real-time quote of ACADIA Pharmaceuticals stock.